Second-wave direct-acting antivirals for hepatitis C: Simeprevir
n/a
Record ID 32014001197
English
Authors' objectives:
The second-wave direct-acting antivirals (DAAs) are prescribed to treat chronic hepatitis C with the objective of achieving sustained viral response and preventing harmful liver damage. These agents were developed to address the issues associated with pegylated interferon, ribavirin, and previously approved DAAs, including lack of response and relapse, resistance, poor safety profile, and burdensome treatment regimen. Second-wave DAA agents include simeprevir, sofosbuvir, and the combination of sofosbuvir and ledipasvir.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=17057
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Hepatitis C
- Antiviral Agents
- Protease Inhibitors
- Simeprevir
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.